Logo image of CLSD

CLEARSIDE BIOMEDICAL INC (CLSD) Stock Fundamental Analysis

NASDAQ:CLSD - Nasdaq - US1850631045 - Common Stock - Currency: USD

0.95  -0.08 (-7.77%)

After market: 0.9998 +0.05 (+5.24%)

Fundamental Rating

3

CLSD gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. CLSD may be in some trouble as it scores bad on both profitability and health. CLSD is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLSD has reported negative net income.
CLSD had a negative operating cash flow in the past year.
In the past 5 years CLSD reported 4 times negative net income.
CLSD had a negative operating cash flow in each of the past 5 years.
CLSD Yearly Net Income VS EBIT VS OCF VS FCFCLSD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -109.31%, CLSD is doing worse than 78.92% of the companies in the same industry.
Industry RankSector Rank
ROA -109.31%
ROE N/A
ROIC N/A
ROA(3y)-52.95%
ROA(5y)-73.6%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLSD Yearly ROA, ROE, ROICCLSD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200 -200 -300

1.3 Margins

CLSD has a better Gross Margin (102.18%) than 99.46% of its industry peers.
The Profit Margin and Operating Margin are not available for CLSD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 102.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLSD Yearly Profit, Operating, Gross MarginsCLSD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50K -100K -150K -200K -250K

More info and screens

3

2. Health

2.1 Basic Checks

CLSD does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLSD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CLSD has more shares outstanding
CLSD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLSD Yearly Shares OutstandingCLSD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
CLSD Yearly Total Debt VS Total AssetsCLSD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -17.75, we must say that CLSD is in the distress zone and has some risk of bankruptcy.
CLSD has a Altman-Z score of -17.75. This is amonst the worse of the industry: CLSD underperforms 84.32% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -17.75
ROIC/WACCN/A
WACC9.77%
CLSD Yearly LT Debt VS Equity VS FCFCLSD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

2.3 Liquidity

A Current Ratio of 4.49 indicates that CLSD has no problem at all paying its short term obligations.
CLSD has a Current ratio of 4.49. This is in the better half of the industry: CLSD outperforms 62.16% of its industry peers.
A Quick Ratio of 4.49 indicates that CLSD has no problem at all paying its short term obligations.
The Quick ratio of CLSD (4.49) is better than 63.24% of its industry peers.
Industry RankSector Rank
Current Ratio 4.49
Quick Ratio 4.49
CLSD Yearly Current Assets VS Current LiabilitesCLSD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

CLSD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.51%, which is quite impressive.
Looking at the last year, CLSD shows a very strong growth in Revenue. The Revenue has grown by 248.55%.
Measured over the past years, CLSD shows a very strong growth in Revenue. The Revenue has been growing by 207.34% on average per year.
EPS 1Y (TTM)29.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)248.55%
Revenue growth 3Y1.4%
Revenue growth 5Y207.34%
Sales Q2Q%20.84%

3.2 Future

The Earnings Per Share is expected to grow by 15.16% on average over the next years. This is quite good.
Based on estimates for the next years, CLSD will show a very strong growth in Revenue. The Revenue will grow by 63.73% on average per year.
EPS Next Y10.1%
EPS Next 2Y6.49%
EPS Next 3Y1.74%
EPS Next 5Y15.16%
Revenue Next Year-75.4%
Revenue Next 2Y-31.29%
Revenue Next 3Y20.95%
Revenue Next 5Y63.73%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
CLSD Yearly Revenue VS EstimatesCLSD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
CLSD Yearly EPS VS EstimatesCLSD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLSD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLSD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLSD Price Earnings VS Forward Price EarningsCLSD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLSD Per share dataCLSD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.49%
EPS Next 3Y1.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLSD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLEARSIDE BIOMEDICAL INC

NASDAQ:CLSD (2/21/2025, 8:10:03 PM)

After market: 0.9998 +0.05 (+5.24%)

0.95

-0.08 (-7.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-18 2025-03-18/amc
Inst Owners20.21%
Inst Owner Change-97.14%
Ins Owners1.49%
Ins Owner Change0.44%
Market Cap72.05M
Analysts84.62
Price Target6.12 (544.21%)
Short Float %1.11%
Short Ratio3.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.25%
Min EPS beat(2)21.12%
Max EPS beat(2)27.38%
EPS beat(4)3
Avg EPS beat(4)13%
Min EPS beat(4)-6.87%
Max EPS beat(4)27.38%
EPS beat(8)4
Avg EPS beat(8)2.97%
EPS beat(12)6
Avg EPS beat(12)-17.59%
EPS beat(16)8
Avg EPS beat(16)-14.87%
Revenue beat(2)1
Avg Revenue beat(2)348.98%
Min Revenue beat(2)-30.34%
Max Revenue beat(2)728.3%
Revenue beat(4)2
Avg Revenue beat(4)169.2%
Min Revenue beat(4)-61.45%
Max Revenue beat(4)728.3%
Revenue beat(8)5
Avg Revenue beat(8)243.24%
Revenue beat(12)6
Avg Revenue beat(12)150.25%
Revenue beat(16)8
Avg Revenue beat(16)103.39%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)8.93%
EPS NQ rev (3m)28.04%
EPS NY rev (1m)0%
EPS NY rev (3m)5.49%
Revenue NQ rev (1m)-16.67%
Revenue NQ rev (3m)44.22%
Revenue NY rev (1m)0%
Revenue NY rev (3m)180.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.35
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.1
BVpS-0.46
TBVpS-0.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -109.31%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 102.18%
FCFM N/A
ROA(3y)-52.95%
ROA(5y)-73.6%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 396.34%
Cap/Sales 8.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.49
Quick Ratio 4.49
Altman-Z -17.75
F-Score4
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)939.64%
Cap/Depr(5y)573.3%
Cap/Sales(3y)13.47%
Cap/Sales(5y)8.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y10.1%
EPS Next 2Y6.49%
EPS Next 3Y1.74%
EPS Next 5Y15.16%
Revenue 1Y (TTM)248.55%
Revenue growth 3Y1.4%
Revenue growth 5Y207.34%
Sales Q2Q%20.84%
Revenue Next Year-75.4%
Revenue Next 2Y-31.29%
Revenue Next 3Y20.95%
Revenue Next 5Y63.73%
EBIT growth 1Y17.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.68%
EBIT Next 3Y1.69%
EBIT Next 5YN/A
FCF growth 1Y-585.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-601.82%
OCF growth 3YN/A
OCF growth 5YN/A